{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:29:46Z","timestamp":1791772186895,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008196","name":"M\u00e9decins Sans Fronti\u00e8res","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004417","name":"Global Fund","doi-asserted-by":"publisher","award":["BLR-C-RSPCMT 2684"],"award-info":[{"award-number":["BLR-C-RSPCMT 2684"]}],"id":[{"id":"10.13039\/100004417","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Only 63% of patients initiating multidrug-resistant\/rifampicin-resistant tuberculosis (MDR\/RR-TB) treatment in 2020 were treated successfully. 24-Week all-oral bedaquiline, pretomanid, and linezolid (BPaL)\u2013based regimens have demonstrated higher rates of treatment success and have been recommended by the World Health Organization. Operational research is urgently required to evaluate these regimens in non-trial settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective cohort study of patients with microbiologically confirmed MDR\/RR-TB and pre\u2013extensively drug-resistant TB (pre-XDR-TB) initiated on BPaL-based regimens in Belarus and Uzbekistan (February 2022\u2013June 2023). All clinical care and research procedures were delivered by treating physicians. After treatment completion, patients were followed up at 6 and 12 months, including collecting sputum to ascertain recurrence. The primary objective was to estimate the effectiveness (cured or treatment completed) and safety (the occurrence of serious adverse events) of BPaL-based regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 677 patients initiated treatment with BPaL-based regimens during the study. We documented successful treatment outcomes in 95.3% (427\/448) of patients with MDR\/RR-TB treated with BPaL plus moxifloxacin and 90.4% (207\/229) of patients with pre\u2013XDR-TB treated with BPaL plus clofazimine. 10.2% (69\/677) experienced serious adverse events including 24 deaths (3.5%), 11 of which occurred during treatment. 83.3% (20\/24) of deaths were not related to TB or TB treatment. Of patients who were successfully treated and completed 12-month follow-up, 0.5% (2\/383) had recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BPaL-based regimens for MDR\/RR-TB and pre\u2013XDR-TB are safe and highly effective in non-trial settings. These regimens should be considered for widespread implementation globally, and further research is needed to evaluate their performance in other key populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf035","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T12:46:24Z","timestamp":1739882784000},"page":"838-845","source":"Crossref","is-referenced-by-count":18,"title":["The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)\u2013Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings\u2014A Prospective Cohort Study in Belarus and Uzbekistan"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-7813","authenticated-orcid":false,"given":"Animesh","family":"Sinha","sequence":"first","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0722-6219","authenticated-orcid":false,"given":"Roland","family":"Klebe","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L","family":"Rekart","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Tashkent ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Alvarez","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Skrahina","sequence":"additional","affiliation":[{"name":"Republican Scientific and Practical Center for Pulmonology and Tuberculosis , Minsk ,","place":["Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8691-1849","authenticated-orcid":false,"given":"Natalia","family":"Yatskevich","sequence":"additional","affiliation":[{"name":"Republican Scientific and Practical Center for Pulmonology and Tuberculosis , Minsk ,","place":["Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varvara","family":"Solodovnikova","sequence":"additional","affiliation":[{"name":"Republican Scientific and Practical Center for Pulmonology and Tuberculosis , Minsk ,","place":["Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzmitry","family":"Viatushka","sequence":"additional","affiliation":[{"name":"Republican Scientific and Practical Center for Pulmonology and Tuberculosis , Minsk ,","place":["Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargiza","family":"Parpieva","sequence":"additional","affiliation":[{"name":"Republican Specialized Scientific and Practical Medical Center of Tuberculosis and Pulmonology , Tashkent ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khasan","family":"Safaev","sequence":"additional","affiliation":[{"name":"Republican Specialized Scientific and Practical Medical Center of Tuberculosis and Pulmonology , Tashkent ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Liverko","sequence":"additional","affiliation":[{"name":"Republican Specialized Scientific and Practical Medical Center of Tuberculosis and Pulmonology , Tashkent ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinaida","family":"Tigay","sequence":"additional","affiliation":[{"name":"Republican Center of Tuberculosis and Pulmonology , Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2527-592X","authenticated-orcid":false,"given":"Soe","family":"Moe","sequence":"additional","affiliation":[{"name":"Republican Center of Tuberculosis and Pulmonology , Nukus ,","place":["Uzbekistan"]},{"name":"M\u00e9decins Sans Fronti\u00e8res, Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Khristusev","sequence":"additional","affiliation":[{"name":"Republican Center of Tuberculosis and Pulmonology , Nukus ,","place":["Uzbekistan"]},{"name":"M\u00e9decins Sans Fronti\u00e8res, Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sholpan","family":"Allamuratova","sequence":"additional","affiliation":[{"name":"Republican Center of Tuberculosis and Pulmonology , Nukus ,","place":["Uzbekistan"]},{"name":"M\u00e9decins Sans Fronti\u00e8res, Nukus ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjar","family":"Mirzabaev","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Tashkent ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0590-0155","authenticated-orcid":false,"given":"Muzaffar","family":"Achilov","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Tashkent ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4922-7130","authenticated-orcid":false,"given":"Nazgul","family":"Samieva","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Tashkent ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lachenal","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne Simone","family":"Merle","sequence":"additional","affiliation":[{"name":"Special Programme of Research and Training in Tropical Diseases (TDR), World Health Organization , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatimata Bintou","family":"Sall","sequence":"additional","affiliation":[{"name":"Special Programme of Research and Training in Tropical Diseases (TDR), World Health Organization , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo Gomez","family":"Restrepo","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Tashkent ,","place":["Uzbekistan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilio","family":"Tan","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Minsk ,","place":["Belarus"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2186-8530","authenticated-orcid":false,"given":"Norman","family":"Sitali","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Saunders","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res , London ,","place":["United Kingdom"]},{"name":"Department of Infection and Immunity, City St. George's University of London , School of Health and Medical Sciences, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"2025110901581047600_ciaf035-B1","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment. Drug-resistant tuberculosis treatment. 2022 update","author":"World Health Organization","year":"2022"},{"key":"2025110901581047600_ciaf035-B2","volume-title":"WHO announces updated definitions of extensively drug-resistant tuberculosis","author":"World Health Organization","year":"2021"},{"key":"2025110901581047600_ciaf035-B3","volume-title":"Global TB report 2023","author":"World Health Organization","year":"2023"},{"key":"2025110901581047600_ciaf035-B4","doi-asserted-by":"crossref","first-page":"e0018019","DOI":"10.1128\/cmr.00180-19","article-title":"The changing paradigm of drug-resistant tuberculosis treatment: successes, pitfalls, and future perspectives","volume":"35","author":"Dookie","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"2025110901581047600_ciaf035-B5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cmi.2017.07.008","article-title":"Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009\u20132013","volume":"24","author":"Zhang","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025110901581047600_ciaf035-B6","doi-asserted-by":"crossref","first-page":"973713","DOI":"10.3389\/fphar.2022.973713","article-title":"Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country","volume":"13","author":"Wahid","year":"2022","journal-title":"Front. Pharmacol"},{"key":"2025110901581047600_ciaf035-B7","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1183\/09031936.00186310","article-title":"Shorter treatment duration for selected patients with multidrug-resistant tuberculosis","volume":"38","author":"Leung","year":"2011","journal-title":"Eur Respir J"},{"key":"2025110901581047600_ciaf035-B8","doi-asserted-by":"crossref","first-page":"22361","DOI":"10.1038\/s41598-023-47094-9","article-title":"Economic burden of multidrug-resistant tuberculosis on patients and households: a global systematic review and meta-analysis","volume":"13","author":"Akalu","year":"2023","journal-title":"Sci Rep"},{"key":"2025110901581047600_ciaf035-B9","doi-asserted-by":"crossref","first-page":"e0000681","DOI":"10.1371\/journal.pgph.0000681","article-title":"Good citizens, perfect patients, and family reputation: stigma and prolonged isolation in people with drug-resistant tuberculosis in Vietnam","volume":"2","author":"Redwood","year":"2022","journal-title":"PLOS Glob Public Health"},{"key":"2025110901581047600_ciaf035-B10","doi-asserted-by":"crossref","first-page":"190035","DOI":"10.1183\/16000617.0035-2019","article-title":"Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives","volume":"28","author":"Pontali","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2025110901581047600_ciaf035-B11","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis\u20142011 update","author":"World Health Organization","year":"2011"},{"key":"2025110901581047600_ciaf035-B12","volume-title":"Treatment guidelines for drug-resistant tuberculosis\u20142016 update","author":"World Health Organization","year":"2016"},{"key":"2025110901581047600_ciaf035-B13","volume-title":"Consolidated guidelines on drug-resistant tuberculosis treatment\u20142019 update","author":"World Health Organization","year":"2019"},{"key":"2025110901581047600_ciaf035-B14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"2025110901581047600_ciaf035-B15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"key":"2025110901581047600_ciaf035-B16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s13063-022-06331-8","article-title":"TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II\u2013III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis","volume":"23","author":"Berry","year":"2022","journal-title":"Trials"},{"key":"2025110901581047600_ciaf035-B17","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampicin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"2025110901581047600_ciaf035-B18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","article-title":"Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial","volume":"12","author":"Nyang\u2019wa","year":"2024","journal-title":"Lancet Resp Med"},{"key":"2025110901581047600_ciaf035-B19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/cid\/ciad312","article-title":"Implementation of bedaquiline, pretomanid, and linezolid in the United States: experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant tuberculosis disease","volume":"77","author":"Haley","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025110901581047600_ciaf035-B20","doi-asserted-by":"crossref","first-page":"100408","DOI":"10.1016\/j.jctube.2023.100408","article-title":"The use of BPaL containing regimen in the MDR\/preXDR TB treatments in Thailand","volume":"34","author":"Sangsayunh","year":"2024","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"2025110901581047600_ciaf035-B21","first-page":"OA865","article-title":"Programmatic management of bedaquiline-pretomanid-linezolid regimens in Georgia","volume":"62","author":"Kiria","year":"2023","journal-title":"Euro Respir J"},{"key":"2025110901581047600_ciaf035-B22","author":"Hamadeh"},{"key":"2025110901581047600_ciaf035-B23","author":"World Health Organization"},{"key":"2025110901581047600_ciaf035-B24","author":"World Health Organization"},{"key":"2025110901581047600_ciaf035-B25","volume-title":"Definitions and reporting framework for tuberculosis\u20142013 revision (updated December 2014 and January 2020)","author":"World Health Organization","year":"2013"},{"key":"2025110901581047600_ciaf035-B26","first-page":"202100804","article-title":"World Health Organization treatment outcome definitions for tuberculosis: 2021 update","volume":"58","author":"World Health Organization","year":"2021","journal-title":"Eur Respir J"},{"key":"2025110901581047600_ciaf035-B27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2025110901581047600_ciaf035-B28","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2025110901581047600_ciaf035-B29","doi-asserted-by":"publisher","DOI":"10.1101\/2024.01.29.24301679","article-title":"Nine-month, all-oral regimens for rifampin-resistant tuberculosis","author":"Guglielmetti","year":"29  2024","journal-title":"medRxiv, doi: 24301679"},{"key":"2025110901581047600_ciaf035-B30","doi-asserted-by":"crossref","first-page":"e3563","DOI":"10.1093\/cid\/ciaa1894","article-title":"Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high human immunodeficiency virus (HIV) burden rural South Africa: a retrospective cohort analysis","volume":"73","author":"Tack","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf035\/61934807\/ciaf035.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/4\/838\/61934807\/ciaf035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/4\/838\/61934807\/ciaf035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T06:58:24Z","timestamp":1762671504000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/4\/838\/8019828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,18]]},"published-print":{"date-parts":[[2025,11,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf035","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,15]]},"published":{"date-parts":[[2025,2,18]]}}}